Connecting via Winsock to STN at pto-stn on port 23

Welcome to STN International! Enter x:X

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS 3	JAN 24	The new and enhanced DPCI file on STN has been released
NEWS 4	JAN 26	Improved Timeliness of CAS Indexing Adds Value to USPATFULL and USPAT2 Chemistry Patents
NEWS 5	JAN 26	Updated MeSH vocabulary, new structured abstracts, and other enhancements improve searching in STN reload of MEDLINE
NEWS 6	JAN 28	CABA will be updated weekly
NEWS 7	FEB 23	PCTFULL file on STN completely reloaded
NEWS 8	FEB 23	STN AnaVist Test Projects Now Available for Qualified Customers
NEWS 9	FEB 25	LPCI will be replaced by LDPCI
NEWS 10	MAR 07	Pricing for SELECTing Patent, Application, and Priority Numbers in the USPAT and IFI Database Families is Now Consistent with Similar Patent Databases on STN
NEWS 11	APR 26	Expanded Swedish Patent Application Coverage in CA/CAplus Provides More Current and Complete Information
NEWS 12	APR 28	The DWPI (files WPINDEX, WPIDS and WPIX) on STN have been enhanced with thesauri for the European Patent Classifications
NEWS 13	MAY 02	MEDLINE Improvements Provide Fast and Simple Access to DOI and Chemical Name Information
NEWS 14	MAY 12	European Patent Classification thesauri added to the INPADOC files, PCTFULL, GBFULL and FRFULL
NEWS 15	MAY 23	Enhanced performance of STN biosequence searches
NEWS 16	MAY 23	Free Trial of the Numeric Property Search Feature in PCTFULL on STN
NEWS 17	JUN 20	STN on the Web Enhanced with New Patent Family Assistant and Updated Structure Plug-In
NEWS 18	JUN 20	INPADOC databases enhanced with first page images
NEWS 19	JUN 20	PATDPA database updates to end in June 2011
NEWS 20	JUN 26	MARPAT Enhancements Save Time and Increase Usability
NEWS 21	JUL 25	STN adds Australian patent full-text database, AUPATFULL, including the new numeric search feature.
NEWS 22	AUG 01	CA Sections Added to ACS Publications Web Editions Platform
NEWS 23	AUG 16	INPADOC: Coverage of German Patent Data resumed, enhanced legal status
NEWS 24	AUG 18	Upgrade now to STN Express, Version 8.5
NEWS 25	SEP 01	CAS Journal Coverage Now Includes Ahead-of-Print Articles for More Than 100 Journal Titles
NEWS 26	SEP 01	Older Versions of STN Express to be Discontinued Beginning in March 2012
NEWS 27	SEP 09	USAN Database Updates Offer Superior Currency on STN(R)

NEWS EXPRESS 18 AUGUST 2011 CURRENT WINDOWS VERSION IS V8.5,

AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:43:55 ON 16 SEP 2011

=> fil reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.69 0.69

FILE 'REGISTRY' ENTERED AT 10:45:49 ON 16 SEP 2011

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 SEP 2011 HIGHEST RN 1332567-70-0
DICTIONARY FILE UPDATES: 15 SEP 2011 HIGHEST RN 1332567-70-0

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s 89-25-8/rn
L1 1 89-25-8/RN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN
RN **89-25-8** REGISTRY
ED Entered STN: 16 Nov 1984
CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Pyrazolin-5-one, 3-methyl-1-phenyl- (8CI)

OTHER NAMES:
CN 1-Phenyl-3-methyl-1H-4,5-dihydropyrazol-5-one
CN 1-Phenyl-3-methyl-2-pyrazolin-5-one
CN 1-Phenyl-3-methyl-5-oxopyrazole
CN 1-Phenyl-3-methyl-5-pyrazolinone
CN 1-Phenyl-3-methyl-5-pyrazolone
CN 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one
CN 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one
CN 3-Methyl-1-phenyl-1H-pyrazol-5-one
CN 3-Methyl-1-phenyl-2-pyrazolin-5-one
CN 3-Methyl-1-phenyl-2-pyrazoline-5-one
CN 3-Methyl-1-phenyl-4,5-dihydropyrazol-5-one
CN 3-Methyl-1-phenyl-4,5-dihydropyrazole-5-one
CN 3-Methyl-1-phenyl-5-pyrazolone
CN 3-Methyl-1-phenylpyrazol-5(4H)-one
CN 3-Methyl-1-phenylpyrazolin-5-one
CN 5-Methyl-2-phenyl-2H-pyrazol-3(4H)-one
CN 5-Methyl-2-phenylpyrazol-3-one
CN C.I. Developer 1
CN Developer Z
CN Edarabone
CN Edaravone
CN MCI 186
CN Methylphenylpyrazolone
CN NCI-C 03952
CN Norantipyrine
CN Norphenazone
CN NSC 12
CN NSC 26139
CN NSC 2629
CN Radicut
DR 12235-58-4, 62495-97-0, 115566-83-1, 72134-66-8, 52224-17-6, 206195-95-1
MF C10 H10 N2 O
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
      CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, DDFU,
      DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IMSRESEARCH,
      IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PS, REAXYSFILE*, RTECS*, SPECINFO,
      TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD, VETU
        (*File contains numerically searchable property data)
    Other Sources: DSL**, EINECS**, TSCA**, WHO
        (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

            3410 REFERENCES IN FILE CA (1907 TO DATE)
              77 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            3442 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 89-25-8/crn
L2   31 89-25-8/CRN

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.66       3.35

FILE 'CAPLUS' ENTERED AT 10:46:14 ON 16 SEP 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 Sep 2011  VOL 155 ISS 13
FILE LAST UPDATED: 15 Sep 2011  (20110915/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Jun 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Jun 2011

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2011.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l1 or l2
          3442 L1
            21 L2
L3        3458 L1 OR L2

=> l3 and (percutaneous and cerebral)
L3 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l3 and (percutaneous and cerebral)
         14067 PERCUTANEOUS
        134426 CEREBRAL
L4           1 L3 AND (PERCUTANEOUS AND CEREBRAL)

=> d l4

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2011 ACS on STN
AN   2005:451191  CAPLUS
DN   142:487534
TI   Percutaneous absorption type cerebral protective agent
IN   Mori, Jun; Horiuchi, Tamaki; Yama, Seijiro; Waki, Hitomi; Shimada, Shingo;
     Hashitani, Hitomi
PA   Lead Chemical Co., Ltd., Japan
```

```
SO   PCT Int. Appl., 27 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2005046680        A1    20050526    WO 2003-JP14362        20031112
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2003280739         A1    20040606    AU 2003-280739         20031112
     CA 2546064            A1    20050526    CA 2003-2546064        20031112
     CA 2546064            C     20110621
     EP 1685837            A1    20060802    EP 2003-772698         20031112
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK
     CN 1878549            A     20061213    CN 2003-80110679       20031112
     CN 100528153          C     20090819
     US 20070148217        A1    20070628    US 2006-579055         20060511
     IN 2006DN02817        A     20070803    IN 2006-DN2817         20060518
     KR 2006123295         A     20061201    KR 2006-7011405        20060609
     KR 1008052            B1    20110113
PRAI WO 2003-JP14362       A     20031112
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   1     THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT  14    THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 10:43:55 ON 16 SEP 2011)

     FILE 'REGISTRY' ENTERED AT 10:45:49 ON 16 SEP 2011
L1             1 S 89-25-8/RN
L2            31 S 89-25-8/CRN

     FILE 'CAPLUS' ENTERED AT 10:46:14 ON 16 SEP 2011
L3          3458 S L1 OR L2
L4             1 S L3 AND (PERCUTANEOUS AND CEREBRAL)

=> s l3 and (aqueous adj2 base)
        229890 AQUEOUS
             1 AQUEOUSES
        229891 AQUEOUS
                  (AQUEOUS OR AQUEOUSES)
             0 ADJ2
        913981 BASE
        192351 BASES
       1028661 BASE
                  (BASE OR BASES)
             0 AQUEOUS ADJ2 BASE
                  (AQUEOUS(W)ADJ2(W)BASE)
L5             0 L3 AND (AQUEOUS ADJ2 BASE)
```

```
=> s l3 and (aqueous)(S)(base)
        229890 AQUEOUS
             1 AQUEOUSES
        229891 AQUEOUS
                 (AQUEOUS OR AQUEOUSES)
        913981 BASE
        192351 BASES
       1028661 BASE
                 (BASE OR BASES)
          2634 (AQUEOUS)(S)(BASE)
L6           0 L3 AND (AQUEOUS)(S)(BASE)

=> s l3 and "aqueous base"
        229890 "AQUEOUS"
             1 "AQUEOUSES"
        229891 "AQUEOUS"
                 ("AQUEOUS" OR "AQUEOUSES")
        913981 "BASE"
        192351 "BASES"
       1028661 "BASE"
                 ("BASE" OR "BASES")
           197 "AQUEOUS BASE"
                 ("AQUEOUS"(W)"BASE")
L7           0 L3 AND "AQUEOUS BASE"

=> s l3 and (cerebral dysfunction)
        134426 CEREBRAL
         90918 DYSFUNCTION
          5915 DYSFUNCTIONS
         95119 DYSFUNCTION
                 (DYSFUNCTION OR DYSFUNCTIONS)
           203 CEREBRAL DYSFUNCTION
                 (CEREBRAL(W)DYSFUNCTION)
L8           0 L3 AND (CEREBRAL DYSFUNCTION)

=> s l3 and "cerebral dysfunction"
        134426 "CEREBRAL"
         90918 "DYSFUNCTION"
          5915 "DYSFUNCTIONS"
         95119 "DYSFUNCTION"
                 ("DYSFUNCTION" OR "DYSFUNCTIONS")
           203 "CEREBRAL DYSFUNCTION"
                 ("CEREBRAL"(W)"DYSFUNCTION")
L9           0 L3 AND "CEREBRAL DYSFUNCTION"

=> d his

     (FILE 'HOME' ENTERED AT 10:43:55 ON 16 SEP 2011)

     FILE 'REGISTRY' ENTERED AT 10:45:49 ON 16 SEP 2011
L1           1 S 89-25-8/RN
L2          31 S 89-25-8/CRN

     FILE 'CAPLUS' ENTERED AT 10:46:14 ON 16 SEP 2011
L3        3458 S L1 OR L2
L4           1 S L3 AND (PERCUTANEOUS AND CEREBRAL)
L5           0 S L3 AND (AQUEOUS ADJ2 BASE)
L6           0 S L3 AND (AQUEOUS)(S)(BASE)
L7           0 S L3 AND "AQUEOUS BASE"
L8           0 S L3 AND (CEREBRAL DYSFUNCTION)
L9           0 S L3 AND "CEREBRAL DYSFUNCTION"
```

```
=> s l3 and (transdermal or patch)
         22088 TRANSDERMAL
             9 TRANSDERMALS
         22089 TRANSDERMAL
                 (TRANSDERMAL OR TRANSDERMALS)
         47293 PATCH
         24659 PATCHES
         63276 PATCH
                 (PATCH OR PATCHES)
L10         17 L3 AND (TRANSDERMAL OR PATCH)

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11          17 DUP REM L10 (0 DUPLICATES REMOVED)

=> d l11 1-17 ibib abs

L11  ANSWER 1 OF 17  CAPLUS  COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER:        2011:185966  CAPLUS
DOCUMENT NUMBER:         154:268719
TITLE:                   Compounded medical composition containing edaravone
                         and nimodipine for protecting brain, and its
                         formulation
INVENTOR(S):             Wang, Rutao; Chen, Tao; Hu, Huijing; Wang, Weijiao;
                         Zhang, Yang
PATENT ASSIGNEE(S):      Xi'an Libang Pharmaceutical Co., Ltd., Peop. Rep.
                         China
SOURCE:                  Faming Zhuanli Shenqing, 15pp.
                         CODEN: CNXXEV
DOCUMENT TYPE:           Patent
LANGUAGE:                Chinese
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     CN 101966182         A     20110209    CN 2010-10291064       20100925
PRIORITY APPLN. INFO.:                      CN 2010-10291064       20100925
AB   The compounded medical composition contains edaravone and nimodipine at a mass
     ratio of 2-30:1-3.  The compounded medical composition also contains
     pharmaceutically acceptable adjuvants from mannitol, sorbitol, sorbic
     acid, potassium sorbate, sodium thiosulfate, and/or EDTA, etc.  The
     compounded medical composition may be used to prepare the medical prepns. (such
     as tablet, sugar coated tablet, thin film coated tablet, enteric coated
     tablet, capsule, hard capsule, soft capsule, oral solution, buccal tablet,
     granule, pill, powder, cream, sublimed preparation, suspension, solution,
     injection, freeze-dried powder injection, fat emulsion injection,
     suppository, plaster, spray, dripping preparation or patch) for protecting
     brain, and preventing and treating cerebrovascular diseases with good
     synergistic effect.

L11  ANSWER 2 OF 17  CAPLUS  COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER:        2010:238350  CAPLUS
DOCUMENT NUMBER:         152:304131
TITLE:                   Compositions and methods of using (R)-pramipexole in
                         combination with other agents for the treatment of
                         neurodegenerative diseases
INVENTOR(S):             Bozik, Michael; Gribkoff, Valentin
PATENT ASSIGNEE(S):      Knopp Neurosciences, Inc., USA
SOURCE:                  PCT Int. Appl., 118pp.
                         CODEN: PIXXD2
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010022140	A1	20100225	WO 2009-US54292	20090819
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2734491	A1	20100225	CA 2009-2734491	20090819
EP 2334185	A1	20110622	EP 2009-808760	20090819
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, AL, BA, RS				
KR 2011071064	A	20110628	KR 2011-7006213	20090819
CN 102186350	A	20110914	CN 2009-80141639	20090819
US 20110190356	A1	20110804	US 2011-59713	20110419
PRIORITY APPLN. INFO.:			US 2008-90094P P	20080819
			US 2008-113680P P	20081112
			WO 2009-US54292 W	20090819

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Pharmaceutical compns. of (R)-pramipexole (preparation included) and one or more secondary therapeutic agents, e.g. dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, antiinflammatory agents, immunomodulators, antiglutamatergics, ion channel blockers, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof, or those related to mitochondrial dysfunction or increased oxidative stress, are disclosed. The compns. and methods of the invention may be used to treat a neurodegenerative disease in a patient.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2010:1127861 CAPLUS
DOCUMENT NUMBER: 153:440825
TITLE: Surface topographies for non-toxic bioadhesion control
INVENTOR(S): Brennan, Anthony B.; Long, Christopher James; Bagan, Joseph W.; Schumacher, James Frederick; Spiecker, Mark M.
PATENT ASSIGNEE(S): University of Florida, USA
SOURCE: U.S. Pat. Appl. Publ., 64pp., Cont.-in-part of U.S. Ser. No. 567,103.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20100226943	A1	20100909	US 2009-550870	20090831
US 20050178286	A1	20050818	US 2004-780424	20040217
US 7650848	B2	20100126	US 2006-567103	20061205
PRIORITY APPLN. INFO.:			US 2004-780424 A2	20040217
			US 2005-202532 A2	20050812
			US 2006-567103 A2	20061205

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to articles and related devices and systems having surface topog. and/or surface elastic properties for providing non-toxic bioadhesion control. An article includes a first plurality of spaced features arranged in a plurality of groupings including repeat units. The spaced features within a grouping are spaced apart at an average distance of about 1 nm to about 500 μm, each feature having a surface that is substantially parallel to a surface on a neighboring feature separated from its neighboring feature. The groupings of features are arranged with respect to one another so as to define a tortuous pathway. The plurality of spaced features provide the article with an engineered roughness index of about 5 to about 20.

L11 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2010:1102644 CAPLUS
DOCUMENT NUMBER: 153:368419
TITLE: Topical skin care composition containing an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant
INVENTOR(S): Kunin, Audrey
PATENT ASSIGNEE(S): DERMAdoctor, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20100221245	A1	20100902	US 2009-395251	20090227
PRIORITY APPLN. INFO.:			US 2009-395251	20090227

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention is directed to a topical skin care composition The composition has the unique ability to treat acne without drying out the user's skin. In particular, the composition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The antibacterial agent may be benzoyl peroxide. Formulation of a topical pharmaceutical containing 0.5% benzoyl peroxide was disclosed.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L11 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:385269 CAPLUS
DOCUMENT NUMBER: 150:359795
TITLE: External preparation for free radical diseases
INVENTOR(S): Sato, Toshiaki
PATENT ASSIGNEE(S): Mikasa Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 28pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009041714	A1	20090402	WO 2008-JP67878	20080925

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2007-248652 A 20070926

AB It is intended to provide an external preparation for free radical diseases which is excellent in **transdermal** and transmucosal absorption properties. An external preparation is obtained by combining 3-methyl-1-phenyl-2-pyrazolin-5-one (I) with a metabolic inhibitor inhibiting the drug metabolism thereof in the skin and/or mucous membranes. For example, the effect of a metabolic inhibitor (sodium sulfite ,cysteine, arginine, benzotriazole, or 2-mercaptobenzoimidazole) on the content of I in a rat skin piece was examined

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:1575359 CAPLUS
DOCUMENT NUMBER: 152:176330
TITLE: Potent skin sensitizers in oxidative hair dye products on the Swedish market
AUTHOR(S): Yazar, Kerem; Boman, Anders; Liden, Carola
CORPORATE SOURCE: Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Swed.
SOURCE: Contact Dermatitis (2009), 61(5), 269-275
CODEN: CODEDG; ISSN: 0105-1873
PUBLISHER: Wiley-Blackwell
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In recent years, the alarming increase in contact allergy to hair dyes has drawn much attention. It has been shown that many of the currently allowed hair dye substances are potent skin sensitizers. To study the prevalence of hair dye substances, categorized as potent skin sensitizer, in oxidative hair dye products on the Swedish market. Ingredient labels of 122 oxidative hair dye products from 20 brands were examined All ingredients were recorded, and the prevalence of hair dye substances categorized as potent skin sensitizers was assessed. According to ingredient labeling, 120 out of 122 examined oxidative hair dye products contained hair dye substances categorized as potent skin sensitizers. More than 80% of the products contained at least four such substances; 37 hair dye substances categorized as potent skin sensitizers were identified, and 10 of these were more prevalent than p-phenylenediamine. Hair dye substances categorized as potent skin sensitizers are very common in oxidative hair dye products. A substantial number of potent skin sensitizers are more frequently used than p-phenylenediamine, while only a few are com. available as **patch** test substances.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:1020322 CAPLUS
DOCUMENT NUMBER: 152:521975
TITLE: Electrophysiological study on differentiation of rat bone marrow stromal stem cells into neuron-like cells in vitro by edaravone
AUTHOR(S): Zeng, Rong; Hu, Zi-bing; Guo, Wei-tao; Lin, Hao; Sun, Xin; Wei, Jin-song; Wu, Shao-ke
CORPORATE SOURCE: Department of Orthopedics, Affiliated Hospital of Guangdong Medical College, Zhanjiang, 524001, Peop. Rep. China
SOURCE: Chinese Journal of Traumatology (English Edition) (2009), 12(3), 167-172
CODEN: CJTRFY; ISSN: 1008-1275
PUBLISHER: Research Institute of Surgery, Daping Hospital
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Objective: To explore the electrophysiol. properties of differentiation of rat bone marrow-derived stromal stem cells (rBMSCs) to neuron-like cells in vitro by edaravone, a new type of free radical scavenger. Methods: Stromal stem cells were separated from rat bone marrow with Ficoll-Paque reagent and expanded in different culture medium in vitro. RBMSCs were induced by edaravone containing serum-free L-DMEM. Morphol. observation and Western blot anal. including the expression of Nav1.6, Kv1.2, Kv1.3, Cav1.2 were performed, and whole **patch**-clamp technique was used. Results: Cyton contraction and long processes were shown in differentiated stromal stem cells. Nav1.6, Kv1.2, Kv1.3 and Cav1.2 were expressed in both differentiated and undifferentiated cells. However, the expression of channel proteins in differentiated cells was up-regulated. Consistently, their resting potential and outward currents were also enhanced in the differentiated cells, which was especially significant in the outward rectifier potassium current. Conclusion: In vitro, neuron-like cells derived from rBMSCs, induced by edaravone, possess electrophysiol. properties of neurons.
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:469126 CAPLUS
DOCUMENT NUMBER: 151:86144
TITLE: A novel administration route for edaravone: I. Effects of metabolic inhibitors on skin permeability of edaravone
AUTHOR(S): Sato, Toshiaki; Mizuno, Keizo; Ishii, Fumiyoshi
CORPORATE SOURCE: Reserch & Development Division, Mikasa Seiyaku Co., Ltd., 2-3-1 Toyotama-Kita, Nerima-ku, Tokyo, 176-8585, Japan
SOURCE: International Journal of Pharmaceutics (2009), 372(1-2), 33-38
CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We examined the effects of metabolic inhibitors on skin permeation of edaravone. SKF-525A, diclofenac sodium (DIC) and indomethacin (IND) were added to supernatant fluid (SF) of hairless rat (HR) skin homogenate. -Cysteine (-Cys) and benzotriazole (BTA), as pharmaceutical additives,

were added to HR skin homogenate SF, and incubated at 37 °C for 30 min. K m and V max values were calculated For determination of edaravone skin permeation from edaravone/hydroxypropyl-β-cyclodextrin (HPβCD) complex solution, HR skin was placed in a Franz diffusion cell, and kept at 37 °C. Edaravone/HPβCD solution that contained -Cys was put into the donor side. The relative activity in skin homogenate SF after co-treatment with IND and SKF-525A decreased to 40.8% of the control. However, DIC and IND had a weak inhibitory effect. For inhibition of edaravone metabolism, -Cys and BTA had no effect on K m value, but V max was significantly decreased compared with controls (*P < 0.05, Tukey-Kramer test). The edaravone skin permeation rate and permeability coefficient from edaravone/HPβCD complex solution with inhibitor were significantly increased compared with those without inhibitor. We suggest that the metabolism inhibitor was useful for the **transdermal** delivery of edaravone.
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2008:948061 CAPLUS
DOCUMENT NUMBER: 149:322981
TITLE: In vitro metabolism study of edaravone in Wistar and hairless rat skin
AUTHOR(S): Sato, Toshiaki; Mizuno, Keizo; Ishii, Fumiyoshi
CORPORATE SOURCE: Research & Development Division, Mikasa Seiyaku Co., Ltd., 2-3-1 Toyotama-Kita, Nerima-ku, Tokyo, 176-8585, Japan
SOURCE: Biological & Pharmaceutical Bulletin (2008), 31(6), 1150-1154
CODEN: BPBLEO; ISSN: 0918-6158
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We investigated the skin metabolism of edaravone as a radical scavenger in Wistar and hairless rat skin. Approx. 1 g of abdominal skin was excised from 10-wk-old Wistar and hairless rats, homogenized in 10 mL saline, and centrifuged at 10000 g for 20 min. The supernatant fluid was used for the examination of edaravone metabolism in the skin, and we also used supernatant fluid that was heated at 80 °C. Edaravone solution (0.05 mL, 2.4 μmol/mL) was added to 0.95 mL Wistar rat and hairless rat skin homogenate supernatant fluids. In Wistar rats, the residual amount of edaravone in skin homogenate supernatant fluid at 37 °C after 0, 5, 10, 20 and 30 min was 61.58 ± 1.65, 41.84 ± 8.52, 35.54 ± 8.62, 19.73 ± 5.99 and 13.89 ± 4.40%, resp. In hairless rats, the residual amount of edaravone in skin homogenate supernatant fluid at 37 °C after 0, 5 and 10 min was 50.19 ± 14.17, 6.71 ± 5.82 and 0.89 ± 0.80%, resp., and edaravone was not detected after 20 min. Although it was thought that metabolic enzyme activity in skin homogenate supernatant fluid was lost following heat treatment at 80 °C, the residual amount of edaravone in our skin homogenate supernatant fluid decreased with time. It is suggested that edaravone metabolism in the skin is necessary for non-enzymic reactions.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2007:868095 CAPLUS
DOCUMENT NUMBER: 147:219409

TITLE: Percutaneous absorption-type chemical agents containing alkali ion water
INVENTOR(S): Okajima, Masahiro; Ishii, Fumiyoshi
PATENT ASSIGNEE(S): A.I. System Products Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 20pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007197349	A	20070809	JP 2006-16666	20060125

PRIORITY APPLN. INFO.: JP 2006-16666 20060125

AB The chemical agents contain skin-penetrating alkali ion water as a percutaneous absorption enhancer. Preferably, the alkali ion water is produced by deoxygenation, electrolysis, and stabilization under ≥4 kg/cm2 pressure of pure water. The amts. of tramadol-HCl penetrated through rat skin, artificial cultured skin, or EVA membrane were higher in 50% electrolyzed alkali ion water than in a phosphate buffer. A cosmetic lotion containing alkali ion water (containing neg. ions), 1,3-butylene glycol, ethoxylated sunflower oil, polyoxyethylene oleyl ether, and EtOH was formulated. The ion water (at 1000-10,000 ppm) showed no acute toxicity to medaka (Oryzias latipes).

L11 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:1147587 CAPLUS
DOCUMENT NUMBER: 145:477853
TITLE: **Transdermal** free-radical inhibitors packaged with oxygen absorbers
INVENTOR(S): Saito, Haruo; Mori, Atsushi; Waki, Hitomi; Hashitani, Akira
PATENT ASSIGNEE(S): Lead Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006298774	A	20061102	JP 2005-118239	20050415

PRIORITY APPLN. INFO.: JP 2005-118239 20050415

AB The invention relates to a pharmaceutical **transdermal** composition containing a free-radical inhibitor, 3-Methyl-1-phenyl-2-pyrazolin-5-one or its salt, wherein the **transdermal** composition is sealed in an oxygen-impermeable packaging material with a oxygen absorber, e.g. Ageless. The **transdermal** composition has improved storage stability.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:167288 CAPLUS
DOCUMENT NUMBER: 144:239959
TITLE: Pyrazolone preparations with improved bioavailability
INVENTOR(S): Sato, Toshiaki
PATENT ASSIGNEE(S): Mikasa Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006052172	A	20060223	JP 2004-235253	20040812
JP 4746856	B2	20110810		

PRIORITY APPLN. INFO.: JP 2004-235253 20040812

AB Title prepns., e.g. oral or parenteral liquid, solid, emulsions, suspensions, etc., contain 3-methyl-1-phenyl-2-pyrazolin-5-one (I) (salts) complexes with cyclodextrin (II) and/or its derivs. as active ingredients. Thus, 1:1 mol I-methyl-β-II complex showed higher solubility in water and better EVA or cellulose membrane permeability than I alone.

L11 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:816861 CAPLUS
DOCUMENT NUMBER: 145:277953
TITLE: Effect of hydroxypropyl-β-cyclodextrin on the **transdermal** delivery of edaravone through hairless rat skin
AUTHOR(S): Sato, Toshiaki; Mizuno, Keizo; Ishii, Fumiyoshi
CORPORATE SOURCE: R & D Div., Mikasa Seiyaku Co., Ltd., Tokyo, 176-8585, Japan
SOURCE: Material Technology (Tokyo, Japan) (2006), 24(2), 79-83
CODEN: MTECFQ
PUBLISHER: Zairyo Gijutsu Kenkyu Kyokai
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB The purpose of this work was to study the permeation through hairless rat skin of the complex of edaravone with 2-hydroxypropyl-β-cyclodextrin (edaravone/HPβCD). High permeability of the drug from the edaravone/HPβCD solution was compared to that of edaravone solution Although the pretreatment of hairless rat skin with 10% HPβCD did not increase the permeability of edaravone, that of 20% ethanol (EtOH) significantly increased it ($P < 0.01$). However, the skin permeability of the drug from the edaravone solution with 20% EtOH and edaravone/HPβCD solution with 20% EtOH significantly decreased compared to those without 20% EtOH ($P < 0.01$). These results showed that edaravone/HPβCD solution increased permeability of edaravone.
OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L11 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2004:412806 CAPLUS
DOCUMENT NUMBER: 140:395557
TITLE: Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one
INVENTOR(S): Mori, Jun; Horiuchi, Tamaki; Yama, Seijiro; Waki, Hitomi; Shimada, Shingo; Hashitani, Hitomi
PATENT ASSIGNEE(S): Lead Chemical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004041270 A1 20040521 WO 2002-JP11518 20021105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2504873 A1 20040521 CA 2002-2504873 20021105
CA 2504873 C 20110426
AU 2002344454 A1 20040607 AU 2002-344454 20021105
EP 1559426 A1 20050803 EP 2002-779994 20021105
EP 1559426 B1 20110209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
CN 1694699 A 20051109 CN 2002-829849 20021105
CN 100372531 C 20080305
JP 4487258 B2 20100623 JP 2004-549555 20021105
AT 497764 T 20110215 AT 2002-779994 20021105
KR 892813 B1 20090410 KR 2005-7007797 20050502
US 20050266062 A1 20051201 US 2005-533534 20050622
HK 1084588 A1 20080822 HK 2006-104915 20060425
PRIORITY APPLN. INFO.: WO 2002-JP11518 W 20021105
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Disclosed are percutaneous absorption prepns. (optionally being in the form of **patches**) which contain as the active ingredient from 0.1 to 30% by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one or its pharmaceutically acceptable salt in an appropriate base, for example, an aqueous base or a rubber base. These prepns. (or **patches**) are excellent percutaneous absorption prepns. (or percutaneous absorption **patches**) showing a high percutaneous absorbability of the active ingredient and little skin irritation. A composition A containing sodium polyacrylate 5, starch acrylate 6, talc 12, concentrate glycerin 29.1 parts, a composition B containing tartaric acid 2.3 and water 30 parts, and a composition C containing 3-methyl-1-phenyl-2-pyrazolin-5-one 3, N-methyl-2-pyrrolidone 8, crotamiton 2 parts were mixed, and then combined with Me acrylate-2-ethylhexyl acrylate copolymer emulsion 2.5, and aluminum hydroxide gel 0.1 parts. The mixed composition was applied on a polyester nonwoven fabric base to obtain a **transdermal patch** of the present invention.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2004:928762 CAPLUS
DOCUMENT NUMBER: 141:384323
TITLE: **Transdermal patches** containing 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone) for treatment of disorders due to free radicals
INVENTOR(S): Kawanami, Hidenobu; Miura, Susumu
PATENT ASSIGNEE(S): Yutoku Pharmaceutical Ind. Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004307364	A	20041104	JP 2003-100379	20030403

PRIORITY APPLN. INFO.: JP 2003-100379 20030403

AB The **patches** comprise a support and an adhesive layer containing edaravone (I) or its pharmacol. acceptable salts and optionally dissolving agents for I or its salts. The **patch** continuously applies I to body and bioabsorption of I can be immediately stopped by removing the **patch** when adverse effects occur. Thus, a polyester release film was coated with a composition containing I, Kraton D 1107 (styrene-isoprene-styrene block copolymer), YS Resin PX 1150N (terpene resin), and liquid paraffin, hot-air dried, and laminated with a polyester support film to give a **patch**. **Transdermal** absorption of I from the **patch** through a hairless mouse skin sheet was examined The absorption was increased by addition of N-methyl-2-pyrrolidone in the adhesive layer.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L11 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2004:271495 CAPLUS
DOCUMENT NUMBER: 140:292660
TITLE: **Transdermal** or transmucosal preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one (salt) for treatment of free radical-caused diseases
INVENTOR(S): Mizuno, Keizo; Sato, Toshiaki; Matsuo, Yumi
PATENT ASSIGNEE(S): Mikasa Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004099486	A	20040402	JP 2002-261495	20020906
JP 4372398	B2	20091125		

PRIORITY APPLN. INFO.: JP 2002-261495 20020906

AB Title prepns. are claimed. Title compound (I) may be in the form of liposomes, microspheres, or nanospheres. Thus, topical application of a solution containing I significantly lowered blood level of lipoperoxide in hyperlipidemic rabbits.

L11 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2005:90168 CAPLUS
DOCUMENT NUMBER: 143:83162
TITLE: Ranking of hair dye substances according to predicted sensitization potency: quantitative structure-activity relationships
AUTHOR(S): Sosted, H.; Basketter, D. A.; Estrada, E.; Johansen, J. D.; Patlewicz, G. Y.
CORPORATE SOURCE: The National Allergy Research Centre for Consumer Products, Department of Dermatology, Gentofte Hospital, University of Copenhagen, Den.
SOURCE: Contact Dermatitis (2004), 51(5/6), 241-254
CODEN: CODEDG; ISSN: 0105-1873
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal

LANGUAGE: English

AB Allergic contact dermatitis following the use of hair dyes is well known. Many chems. are used in hair dyes and it is unlikely that all cases of hair dye allergy can be diagnosed by **patch** testing with p-phenylenediamine (PPD). The objectives of this study are to identify all hair dye substances registered in Europe and to provide their tonnage data. The sensitization potential of each substance was then estimated by a quant. structure-activity relationship (QSAR) model and the substances were ranked according to their predicted potency. A cluster anal. was performed to help select a number of chemical diverse hair dye substances that could be used in subsequent clin. work. Various information sources, including the Inventory of Cosmetics Ingredients, new regulations on cosmetics, data on total use and ChemId (the Chemical Search Input website provided by the National Library of Medicine), were used to identify the names and structures of the hair dyes. A QSAR model, developed with the help of exptl. local lymph node assay data and topol. sub-structural mol. descriptors (TOPS-MODE), was used to predict the likely sensitization potential. Predictions for sensitization potential were made for the 229 substances that could be identified by a chemical structure, the majority of these hair dyes (75%) being predicted to be strong/moderate sensitizers. Only 22% were predicted to be weak sensitizers and 3% were predicted to be extremely weak or non-sensitizing. Eight of the most widely used hair dye substances were predicted to be strong/moderate sensitizers, including PPD which is the most commonly used hair dye allergy marker in **patch** testing. A cluster anal. by TOPS-MODE descriptors as inputs helped us group the hair dye substances according to their chemical similarity. This would facilitate the selection of potential substances for clin. **patch** testing. A **patch**-test series with potent, frequently used, substances representing various chemical clusters is suggested. This may prove useful in diagnosing PPD-neg. patients with symptoms of hair dye allergy and would provide some clin. validation of the QSAR predictions.

OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)

REFERENCE COUNT: 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:43:55 ON 16 SEP 2011)

FILE 'REGISTRY' ENTERED AT 10:45:49 ON 16 SEP 2011
L1 1 S 89-25-8/RN
L2 31 S 89-25-8/CRN

FILE 'CAPLUS' ENTERED AT 10:46:14 ON 16 SEP 2011
L3 3458 S L1 OR L2
L4 1 S L3 AND (PERCUTANEOUS AND CEREBRAL)
L5 0 S L3 AND (AQUEOUS ADJ2 BASE)
L6 0 S L3 AND (AQUEOUS)(S)(BASE)
L7 0 S L3 AND "AQUEOUS BASE"
L8 0 S L3 AND (CEREBRAL DYSFUNCTION)
L9 0 S L3 AND "CEREBRAL DYSFUNCTION"
L10 17 S L3 AND (TRANSDERMAL OR PATCH)
L11 17 DUP REM L10 (0 DUPLICATES REMOVED)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	96.35	99.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.79	-14.79

STN INTERNATIONAL LOGOFF AT 10:52:19 ON 16 SEP 2011